AI-generated analysis. Always verify with the original filing.
Bone Biologics Corporation filed a prospectus supplement with the U.S. Securities and Exchange Commission on March 13, 2026. The filing includes exhibits consisting of an opinion and consent from Harter Secrest & Emery LLP.
Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On March 13, 2026, Bone Biologics Corporation (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) w ith the U.S. Securitie
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Harter Secrest & Emery LLP 23.1 Consent of Harter Secrest & Emery LLP (in